Isatuximab and Iberdomide as Immunotherapy for High Risk in Smouldering Myeloma

This trial is testing a combination of two immunotherapy drugs — isatuximab and iberdomide — in people with smouldering multiple myeloma (SMM), a pre-cancerous blood condition that has a high risk of progressing to full multiple myeloma. The goal is to see whether early treatment can delay or prevent progression. **You may be eligible if...** - You are 18 or older - You have been diagnosed with smouldering multiple myeloma within the past 5 years - Your SMM is classified as intermediate or high risk, and that classification was made within the last 2 years - You have not yet developed full-blown multiple myeloma requiring treatment **You may NOT be eligible if...** - Your SMM has already progressed to active multiple myeloma - You have other health conditions that make this treatment unsafe - You have already received treatment for your myeloma Talk to your doctor to see if this trial is right for you.